Child Subject Dies in Gene Editing Clinical Trial Developed by Huida Gene
In August 2025, a subject in the high-dose group of Huida Gene's HG302 Duchenne muscular dystrophy gene editing clinical trial died from a severe immune reaction triggered by AAV, and the incident was not disclosed until about a year later.